All trading involves risk. Contracts for Difference (CFDs) are complex instruments and may not be suitable for all investors. Please refer to Risk Disclosure and Risk Fact Sheet on Capital.com/en-sg.
Open platformOpen platform

Lucid Diagnostics Q3 revenue misses analyst expectations

By Reuters News


Overview

  • US cancer diagnostics firm's Q3 revenue missed analyst expectations

  • Adjusted loss per share for Q3 met analyst expectations

  • Company secured nationwide Medicare reimbursement for EsoGuard, expects revenue growth to accelerate


Outlook

  • Company expects commercial acceleration and revenue growth following nationwide Medicare reimbursement for EsoGuard

  • Lucid says near-term growth depends on commercial and operational execution

  • Company is focused on expanding access to EsoGuard for Medicare beneficiaries and increasing test volumes


Result Drivers

  • MEDICARE REIMBURSEMENT - Co said nationwide Medicare coverage for EsoGuard marked a shift to commercial acceleration and revenue growth

  • RECORD TEST VOLUME - Co reported record monthly EsoGuard test volume in October, following Medicare payments

  • COMMERCIAL EXPANSION - Co said it is expanding coverage through additional health plans and VA programs


Company press release: Full Story


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Revenue

Miss

$1.20 mln

$1.64 mln (5 Analysts)

Q3 Adjusted Loss Per Share

Meet

$0.06

$0.06 (4 Analysts)


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

  • Wall Street's median 12-month price target for Lucid Diagnostics Inc is $3.00, about 686.6% above its November 11 closing price of $0.38


Reuters Recommended Reads

  • Nov 9 - OraSure Technologies Q3 revenue rises, gross margin improves

  • Nov 9 - Oncology firm Delcath Systems' Q3 revenue beats on Hepzato growth

  • Nov 9 - US FDA orders new eye risk warnings for Ozempic, Zepbound


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.